Gyroscope Therapeutics Secures $148 Million for AMD Gene Therapy Trials, Signaling Progress for Ocular Diseases
London, UK – The inherited retinal disease (IRD) community is closely watching advancements in ocular gene therapy, and recent news from Gyroscope Therapeutics offers a promising development. The company announced it has successfully raised $148 million in a Series C funding round to further its gene therapy trials for age-related macular degeneration (AMD). While AMD is distinct from many IRDs, progress in gene therapy for any ocular condition often paves the way for broader applications, offering hope for a future with more treatment options for various forms of vision loss.
Fierce Biotech reported on March 26, 2021, that this significant investment positions Gyroscope Therapeutics to advance its pipeline of ocular gene therapies. The funding will be allocated across three clinical trials, including continued studies for its lead candidate, GT005. GT005 is an investigational gene therapy designed to address geographic atrophy (GA), an advanced form of dry AMD, which is a leading cause of blindness.
Gyroscope's approach with GT005 is notable as it aims to increase the production of complement factor I (CFI). CFI helps regulate the complement system, which is part of the body's immune response. In AMD, an overactive complement system is believed to contribute to the disease's progression. By boosting CFI, the therapy seeks to dampen this overactivity and potentially slow down the degeneration of the macula. Unlike some gene therapies that correct genetic defects, Gyroscope's strategy focuses on modulating a biological pathway implicated in the disease. GT005 is being studied as a single dose treatment.
For patients and families affected by ocular diseases, this funding represents continued momentum in the quest for new treatments. While GT005 specifically targets AMD, successful clinical trials and regulatory approvals in one area of ocular gene therapy can accelerate research and development for other inherited retinal conditions. The investment underscores confidence in gene therapy as a powerful tool to combat vision loss. Gyroscope Therapeutics also indicated it expects to consider additional capital-raising options this year, potentially including an initial public offering (IPO).
This development highlights the ongoing commitment within the biotech sector to explore innovative solutions for retinal diseases. The progress of GT005 through clinical trials will be a key indicator of the potential for gene therapy to offer lasting relief for a wider range of vision-threatening conditions.
Source: Fierce Biotech, published March 26, 2021.